Morepen Labs. (MOREPENLAB)
Slow GrowerFairStock Score: 33/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹84.19 |
| Market Cap | ₹4,613.22 Cr |
| P/E Ratio | 32.89 |
| ROCE | 15.08% |
| ROE | 5.04% |
| Dividend Yield | 0.24% |
| Profit Growth | 599.65% |
| Debt/Equity | 0.17 |
| Sales Growth | 44.2% |
| Promoter Holding | 35.65% |
| 52-Week Range | ₹33.05 — ₹150.8 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹22.17 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Morepen Labs strikes me as a business that earns a living but not a wonderful one. At ₹42.69, the market prices it at ₹2,393 crore, which is 31 times earnings. That would be acceptable if profits were growing fast, but they grew only 3.07% over the latest period, while sales rose 6.93%. In other words, the company is not converting its top-line growth into shareholder earnings. The PEG ratio of 6.27 confirms the valuation is far ahead of growth. Graham taught me to treat a P/E above 30 with suspicion unless the company has a wide moat and demonstrable earning power. Morepen's ROE is just 5.04%, meaning the ₹21.16 book value you pay 2.02 times for is generating little return. Even ROCE of 15.08% cannot rescue the overall picture, because the equity return is what ultimately matters to minority shareholders. The balance sheet is respectable: debt-equity is only 0.13 and the Piotroski F-score of 7 suggests no immediate financial distress. The latest quarter, with sales of ₹484 crore and net profit of ₹28 crore, shows a decent operating snapshot, but one quarter does not make an investment. Promoter holding of 35.65% is not a strong sign of aligned skin in the game, and the dividend yield of 0.46% offers negligible compensation while waiting. The stock has fallen from ₹83.50 to around ₹42.69, which may tempt bargain hunters, but a falling price without improving fundamentals is a value trap, not a bargain. I need margins of safety: a lower price, higher return on equity, or clear evidence of a durable competitive advantage. As it stands, Morepen is a slow grower with cyclical leanings and no compelling margin of safety.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer